NCT02104986View on ClinicalTrials.gov

A Multicenter Study to Evaluate a Risk-adapted Strategy for Treatment of Extra Cranial Non Seminomateous Malignant Germ Cell Tumour in Children and Adolescent

PHASE2CompletedINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

May 12, 2014

Primary Completion Date

October 14, 2021

Study Completion Date

October 14, 2021

Conditions
Extra Cranial Non Seminomateous Malignant Germ Cell Tumour
Interventions
DRUG

Velbe-Bleomycin-Cisplatin

Limitation of the number of chemotherapy courses (≤ 4) after the achievement of a clinical and biological response in NSMGCT patients treated with cisplatin-based chemotherapy, in order to reduce treatment long-term effects

DRUG

Vepeside-ifosfamide-Cisplatin

Trial Locations (27)

13385

Hopital de La Timone, Marseille

14033

CHU, Caen

21079

CHU, Dijon

25030

CHRU, Besançon

26609

Chu Morvan, Brest

31059

CHU, Toulouse

33076

CHU, Bordeaux

34295

CHU, Montpellier

35203

CHU, Rennes

37044

CHRU, Tours

42055

CHRU, Saint-Etienne

44093

CHU, Nantes

49033

CHU, Angers

51092

CHU, Reims

54511

CHU, Nancy

59000

Centre Oscar Lambret, Lille

63003

Chu Estaing, Clermont-Ferrand

67098

CHRU, Strasbourg

75005

Institut Curie, Paris

75012

Hopital Trousseau, Paris

76031

CHU, Rouen

80054

CHU, Amiens

86021

CHU, Poitiers

87042

CHU, Limoges

94805

Institut Gustave Roussy, Villejuif

97405

Hopital Felix Guyon, Saint-Denis

06202

CHU, Nice

All Listed Sponsors
lead

Centre Leon Berard

OTHER

NCT02104986 - A Multicenter Study to Evaluate a Risk-adapted Strategy for Treatment of Extra Cranial Non Seminomateous Malignant Germ Cell Tumour in Children and Adolescent | Biotech Hunter | Biotech Hunter